JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CANA/MET XR FDC

First Posted Date: 2014-01-17

Last Posted Date: 2014-04-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT02039245

Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CANA/MET XR FDC

First Posted Date: 2014-01-17

Last Posted Date: 2014-07-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 24

Registration Number: NCT02039258

A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers

Completed

Conditions: Lupus Erythematosus, Cutaneous
Lupus Erythematosus, Discoid
Lupus Erythematosus, Systemic
Healthy

Interventions: Procedure: Skin biopsy
Procedure: Blood collection
Procedure: Urine collection

First Posted Date: 2014-01-13

Last Posted Date: 2016-12-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 77

Registration Number: NCT02034344

A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants

Phase 3

Completed

Conditions: Helminth Infections

Interventions: Drug: Placebo
Drug: Mebendazole

First Posted Date: 2014-01-13

Last Posted Date: 2016-11-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 295

Registration Number: NCT02034162

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Canagliflozin, 100 mg
Drug: Canagliflozin, 300 mg

First Posted Date: 2014-01-01

Last Posted Date: 2016-10-31

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 218

Registration Number: NCT02025907

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Biological: adalimumab 40 mg
Biological: sirukumab 100 mg
Biological: sirukumab 50 mg
Drug: Placebo

First Posted Date: 2013-12-24

Last Posted Date: 2017-10-26

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 559

Registration Number: NCT02019472

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Canagliflozin, 100 mg
Drug: Canagliflozin, 300 mg

First Posted Date: 2013-12-12

Last Posted Date: 2018-01-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 59

Registration Number: NCT02009488

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: 600 mg CNTO 3157
Biological: 100 mg CNTO 3157
Biological: 300 mg CNTO 3157
Drug: Placebo

First Posted Date: 2013-12-11

Last Posted Date: 2014-09-30

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 40

Registration Number: NCT02008279

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Canagliflozin 50 mg
Drug: Canagliflozin 100 mg
Drug: Canagliflozin 300 mg
Drug: Placebo

First Posted Date: 2013-12-04

Last Posted Date: 2017-03-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 17

Registration Number: NCT02000700

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

Phase 2

Completed

Conditions: Treatment Resistant Depressive Disorder

Interventions: Drug: Esketamine 14 mg
Drug: Esketamine 84 mg
Drug: Esketamine 56 mg
Drug: Esketamine 28 mg
Drug: Placebo

First Posted Date: 2013-12-03

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 108

Registration Number: NCT01998958

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy